Monoclonal antibodies against Wnt-1 and Wnt-2 have shown efficacy in inhibiting the Wnt pathway, leading to tumor suppression in cancers such as melanoma, sarcoma, CRC, and NSCLC.683,684 Fzds and LRP5/6 are critical receptors within the Wnt pathway. Here, LRP5 is linked to cancer.